| 000 | 01696 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517075437.0 | ||
| 264 | 0 | _c20161213 | |
| 008 | 201612s 0 0 eng d | ||
| 022 | _a1861-387X | ||
| 024 | 7 |
_a10.1007/s10014-016-0248-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOkamoto, Saori | |
| 245 | 0 | 0 |
_aBevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas. _h[electronic resource] |
| 260 |
_bBrain tumor pathology _cApr 2016 |
||
| 300 |
_a129-36 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aBecaplermin |
| 650 | 0 | 4 |
_aBevacizumab _xpharmacology |
| 650 | 0 | 4 |
_aBrain Neoplasms _xblood supply |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aFatal Outcome |
| 650 | 0 | 4 |
_aFibroblast Growth Factor 2 _xgenetics |
| 650 | 0 | 4 |
_aGene Expression _xdrug effects |
| 650 | 0 | 4 |
_aGlioma _xblood supply |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 | _aNeoplasm Recurrence, Local |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-sis _xgenetics |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xgenetics |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor Receptor-1 _xgenetics |
| 700 | 1 | _aNitta, Masayuki | |
| 700 | 1 | _aMaruyama, Takashi | |
| 700 | 1 | _aSawada, Tatsuo | |
| 700 | 1 | _aKomori, Takashi | |
| 700 | 1 | _aOkada, Yoshikazu | |
| 700 | 1 | _aMuragaki, Yoshihiro | |
| 773 | 0 |
_tBrain tumor pathology _gvol. 33 _gno. 2 _gp. 129-36 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10014-016-0248-6 _zAvailable from publisher's website |
| 999 |
_c25684028 _d25684028 |
||